Cargando…
The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report
RATIONALE: Most patients with hepatocellular carcinoma (HCC) have lost the chance of radical treatment at the time of their visit, and the prognosis of metastatic HCC is even worse. Sorafenib is currently regarded as a first-line systemic therapy in patients with advanced and metastatic HCC. Apatini...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer Health
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310601/ https://www.ncbi.nlm.nih.gov/pubmed/30544412 http://dx.doi.org/10.1097/MD.0000000000013388 |